FXYD2 and glioma: On the one hand, FXYD1 was downregulated in almost all cancers indicating a promising pan‐cancer biomarker in the future, while FXYD2‐FXYD5 failed to exhibit the specific tendency in gliomas compared with other cancers (Figure S2).